0001209191-20-011040.txt : 20200220
0001209191-20-011040.hdr.sgml : 20200220
20200220161011
ACCESSION NUMBER: 0001209191-20-011040
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200218
FILED AS OF DATE: 20200220
DATE AS OF CHANGE: 20200220
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Flynn Daniel Lee
CENTRAL INDEX KEY: 0001713712
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38219
FILM NUMBER: 20635152
MAIL ADDRESS:
STREET 1: C/O DECIPHERA PHARMACEUTICALS, LLC
STREET 2: 500 TOTTEN POND ROAD
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Deciphera Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001654151
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 200299725
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 SMITH STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 781-209-6400
MAIL ADDRESS:
STREET 1: 200 SMITH STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
FORMER COMPANY:
FORMER CONFORMED NAME: Deciphera Pharmaceuticals, LLC
DATE OF NAME CHANGE: 20150928
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-02-18
0
0001654151
Deciphera Pharmaceuticals, Inc.
DCPH
0001713712
Flynn Daniel Lee
C/O DECIPHERA PHARMACEUTICALS, INC.
200 SMITH STREET
WALTHAM
MA
02451
0
1
0
0
Chief Scientific Officer
Common Stock
2020-02-18
4
A
0
7040
0.00
A
98446
D
Common Stock
91020
I
By Daniel L. Flynn Irrevocable Trust
Stock Option (Right to Buy)
54.87
2020-02-18
4
A
0
42190
0.00
D
2030-02-17
Common Stock
42190
42190
D
The reporting person was awarded 7,040 Restricted Stock Units under the 2017 Stock Option and Incentive Plan. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's Common Stock. The Restricted Stock Units shall vest in equal 25% installments on February 15, 2021, February 15, 2022, February 15, 2023 and February 15, 2024, subject to continued service through such dates. The Restricted Stock Units may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
This stock option award was issued pursuant to Issuer's 2017 Stock Option and Incentive Plan. The option vests in 48 equal monthly installments over a 4-year period following the vesting commencement date of 2/18/2020, subject to continued service through such dates.
/s/ Thomas P. Kelly, Attorney-in-Fact
2020-02-20